Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | BAD | Q92934 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 2/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21747335 | 0.87 | AKR1C1 (0.39) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL21747255 | 0.86 | HSD11B1 (0.38) | HSD11B1 | |
| SCHEMBL21747330 | 0.85 | HSD11B1 (0.35) | HSD11B1BCL2L1BADPOLBFABP4 | |
| SCHEMBL21747384 | 0.85 | AKR1C1 (0.40) | POLBCYP2C9CYP2C19KMT2AMEN1 | |
| SCHEMBL25544091 | 0.84 | HSD11B1 (0.33) | HSD11B1BCL2L1BADPOLBCYP3A4 | |
| SCHEMBL21747365 | 0.82 | CTSK (0.39) | CYP3A4CYP2C9CYP2C19KMT2AMEN1 | |
| SCHEMBL21747206 | 0.82 | FASN (0.38) | POLBCYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL21765536 | 0.79 | ITGB1 (0.33) | CYP2C9CYP2C19KMT2AMEN1ALDH1A1 | |
| SCHEMBL21765539 | 0.75 | POLB (0.33) | HSD11B1POLBALDH1A1 | |
| SCHEMBL21747308 | 0.74 | MAPK1 (0.33) | SLC22A12KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970495-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2024-04-30 | — | — | US | disclosed |
| US-11945817-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2024-04-02 | — | — | US | disclosed |
| US-20230257379-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257379-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257379-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230242527-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230242527-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230242527-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-03 | — | — | US | disclosed |
| US-11655249-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11655249-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2023-05-23 | — | — | US | disclosed |
| US-20210253570-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2021-08-19 | — | — | US | disclosed |
| US-20210253570-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2021-08-19 | — | — | US | disclosed |
| CN-113004271-A | Indolizine derivative and application thereof in medicine | 杭州安道药业有限公司 | 2021-06-22 | — | — | CN | disclosed |
| US-11021478-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2021-06-01 | — | — | US | disclosed |
| US-11021478-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2021-06-01 | — | — | US | disclosed |
| CN-108484598-B | Indolizine derivative and application thereof in medicine | 杭州安道药业有限公司 | 2021-03-02 | — | — | CN | disclosed |
| US-20200165242-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2020-05-28 | — | — | US | disclosed |
| US-20200165242-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2020-05-28 | — | — | US | disclosed |
| EP-3613742-A1 | INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE | Kind Pharmaceutical (CN) | 2020-02-26 | — | — | EP | disclosed |
| EP-3613742-A1 | INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE | Kind Pharmaceutical (CN) | 2020-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257379-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | HSD11B1 44/4885BCL2L1 4698/4885BAD 1636/4885 |
| US-11021478-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | HSD11B1 44/4885BCL2L1 4698/4885BAD 1636/4885 |
| US-11970495-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | HSD11B1 44/4885BCL2L1 4698/4885BAD 1636/4885 |
| US-20230242527-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | HSD11B1 44/4885BCL2L1 4698/4885BAD 1636/4885 |
| US-11945817-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | HSD11B1 44/4885BCL2L1 4698/4885BAD 1636/4885 |
| US-20210253570-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | HSD11B1 44/4885BCL2L1 4698/4885BAD 1636/4885 |
| US-11655249-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | HSD11B1 44/4885BCL2L1 4698/4885BAD 1636/4885 |
| US-20200165242-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | HSD11B1 44/4885BCL2L1 4698/4885BAD 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.